

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Holtzman, Douglas A.
 Application No.: 09/782,980
 Filed: February 13, 2001
 For: NOVEL ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, AND STMST PROTEIN AND NUCLEIC ACID MOLECULES AND USES THEREFOR

Group No.: 1652

Examiner: Maryam Monshipouri, Ph.D.

Commissioner for Patents
 Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Madam:

REMARKS

In response to the Restriction Requirement dated June 12, 2003 (Paper No. 11), Applicants hereby elect Group 9b, drawn to isolated DNA sequences encoding human STMST-2 polypeptides, host cells, kits comprising said sequences, and methods of expressing said sequences (claims 1-7, 12, 18, and 53-54), with traverse. This election is made without prejudice to Applicant's right to pursue the non-elected subject matter in other applications in the event a generic claim is not found allowable.

Applicants respectfully traverse the present restriction and reserve the right to petition therefrom under 37 C.F.R. § 1.144 and for the reasons set forth below.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

☒ with sufficient postage as first class mail.


☐ as "Express Mail Post Office to Address" Mailing Label No.

37 C.F.R. SECTION 1.10*

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature



Date: July 14, 2003

Mary MacKinnon

(type or print name of person certifying)

#12
 S.G.J.
 7/24/03

Elected as Separate Species of a Common Genus

Applicants submit that the separate nucleic acid sequences encoding SEQ ID NOs:71 and 74 (STMST-1 and STMST-2, respectively) should be examined together, as species of a common genus. As seen in the enclosed protein sequence alignment (Exhibit A), the sequences of SEQ ID NOs:71 and 74 (and the nucleic acid sequences encoding them) are related in that SEQ ID NO:74 (STMST-2), which is a 609 residue protein, comprises the majority portion of SEQ ID NO:71 (STMST-1), which is a 297 residue protein. Both protein sequences share the first 262 residues, which constitute over 88% of the entire length of the STMST-1 protein. The nucleic acid sequence encoding the protein sequences are even more similar, as evidenced by the enclosed alignment of the open reading frame encoding STMST-1 and a truncated version of the open reading frame encoding STMST-2 (Exhibit B, showing 93% sequence identity over the length of the STMST-1 open reading frame).

The inclusion of both nucleic acids which encode SEQ ID NOs:71 and 74 in the current election does not pose a serious examination burden on the Examiner. In fact, it would require virtually the same search and examination, since searching and examining nucleic acids that encode SEQ ID NO:74 includes by necessity a search and examination of the nucleic acids that encode SEQ ID NO:71 (SEQ ID NO:71 shares residues 1-262 of SEQ ID NO:74).

This paper is being filed timely, as it is believed that no extensions of time are required. In the event any extensions of time are deemed necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

July 14, 2003

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By


Paul J. Pagliarini

Registration No. 52,498

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-761-6865

Facsimile - 617-551-8820

Received from < 617 551 8820 > at 7/14/03 3:52:43 PM [Eastern Daylight Time]

07/14/03 16:01 FAX 617 551 8820

MILLENNIUM

005

STMST1 --DCL---P
: :
STMST2 HSDSLGSAS

Received from < 617 551 8820 > at 7/14/03 3:52:43 PM [Eastern Daylight Time]

```
>stmst1
>stmst2 (truncated)
scoring matrix: DNA, gap penalties: -16/-4
93.0% identity; Global alignment score: 3863
```

/tmp/s	ATGAGTGTAGACGGCGCTGCCCTGGCAGTGCAAGTGGCTGGCTGGTATGTGGGGGCCTC	10	20	30	40	50	60
stmst2	ATGAGTGTAGACGGCGCTGCCCTGGCAGTGCAAGTGGCTGGCTGGTATGTGGGGGCCTC	10	20	30	40	50	60
/tmp/s	TCCCTGCTGGCCAATGCCCTGGGTCATCCTCAGCGTTGGCGCCAAAGCAGAAGTGAAG	70	80	90	100	110	120
stmst2	TCCCTGCTGGCCAATGCCCTGGGTCATCCTCAGCGTTGGCGCCAAAGCAGAAGTGAAG	70	80	90	100	110	120
/tmp/s	CCCCTGGAGTTCCTGCTGTGTACGCTCGCGGCACCACCATGCTAAAATGTGCCGTGCC	130	140	150	160	170	180
stmst2	CCCCTGGAGTTCCTGCTGTGTACGCTCGCGGCACCACCATGCTAAAATGTGCCGTGCC	130	140	150	160	170	180
/tmp/s	ATCGCCACCTACTCCGTGGTGCAAGTCCGGCGGCGAGCGCCCGACTTCGAGTGGAATGAG	190	200	210	220	230	240
stmst2	ATCGCCACCTACTCCGTGGTGCAAGTCCGGCGGCGAGCGCCCGACTTCGAGTGGAATGAG	190	200	210	220	230	240
/tmp/s	GGTCTCTGCAAGGTCTTCGTGTCCACCTTCTACACCTCACCCCTGGCCACCTGTTCTCT	250	260	270	280	290	300
stmst2	GGTCTCTGCAAGGTCTTCGTGTCCACCTTCTACACCTCACCCCTGGCCACCTGTTCTCT	250	260	270	280	290	300
/tmp/s	GTCACCTCCCTCTCCTACCACCGCATGTGGATGGTCTGCTGGCTGTCAACTACCGGCTG	310	320	330	340	350	360
stmst2	GTCACCTCCCTCTCCTACCACCGCATGTGGATGGTCTGCTGGCTGTCAACTACCGGCTG	310	320	330	340	350	360
/tmp/s	AGCAATGCCAAGAAGCAGCGGTGCACACAGTCATGGGTATCTGGATGGTGTCTTCATC	370	380	390	400	410	420
stmst2	AGCAATGCCAAGAAGCAGCGGTGCACACAGTCATGGGTATCTGGATGGTGTCTTCATC	370	380	390	400	410	420
/tmp/s	CTGTGGCCCTGCCCTGGCTGGCAGCACACAGCGAGCGCTTCTACACCCATGGC	430	440	450	460	470	480
stmst2	CTGTGGCCCTGCCCTGGCTGGCAGCACACAGCGAGCGCTTCTACACCCATGGC	430	440	450	460	470	480
/tmp/s	TGCCGCTTCATCGTGGCTGAGATCGGCCTGGGCTTTGGCGTCTGCTTCTGCTGTGTG	490	500	510	520	530	540
stmst2	TGCCGCTTCATCGTGGCTGAGATCGGCCTGGGCTTTGGCGTCTGCTTCTGCTGTGTG	490	500	510	520	530	540
/tmp/s	GGCGGCAGCGTGGCCATGGGCGGTGATCTGCACAGCCATCGCCCTCTTCCAGACCGCTG	550	560	570	580	590	600
stmst2	GGCGGCAGCGTGGCCATGGGCGGTGATCTGCACAGCCATCGCCCTCTTCCAGACCGCTG	550	560	570	580	590	600

/tmp/s	610	620	630	640	650	660
	GTGCAGGTGGGGCCAGGCCGACCA	CGCGCTTCACCGTGCCACCATCGTGGTGGAG				
stmst2	610	620	630	640	650	660
	GTGCAGGTGGGGCCAGGCCGACCA	CGCGCTTCACCGTGCCACCATCGTGGTGGAG				
/tmp/s	670	680	690	700	710	720
	GACGCGCAGGGCAAGCGGCGCTCC	TCCATCGATGCTCGAGCCCGCAAACCTCTCTG				
stmst2	670	680	690	700	710	720
	GACGCGCAGGGCAAGCGGCGCTCC	TCCATCGATGCTCGAGCCCGCAAACCTCTCTG				
/tmp/s	730	740	750	760	770	780
	CAGACCACGGGCTCGTGACCA	CCATAGTCTTCATCTACGACTGCCTCATGGGCTTCCCT				
stmst2	730	740	750	760	770	780
	CAGACCACGGGCTCGTGACCA	CCATAGTCTTCATCTACGACTGCCTCATGGGCTTCCCT				
/tmp/s	790	800	810	820	830	
	GTGCTGGACTCTACGCCCATCC	CCGAAAGTCTGCAGTGAGACAGGG-AGAGGACTGG--				
stmst2	790	800	810	820	830	
	GTGCTGGTGCTGAGCTTCAGC	AGC-----CTGCGGGCCGACGCCTCAGCGCCCTGGAT				
/tmp/s	840	850	860	870	880	890
	GGCAAAGACCA	GCCTGAGGGGTTTCAT--CCAAGCAGCAGGCAAGACTGCCCTTCC-C				
stmst2	840	850	860	870	880	890
	GGCACTCTGCGTGCTGTG	TGCTCCGTGGCCAGGCCCTGCTGCTGCTGTGTTCCCTC				

Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Patents, Washington, DC 20231.

Practitioner's Docket No. MPI00-5440MNIM

PATENT

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

On July 14, 2003.



Signature

Mary MacKinnon

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

Response to Restriction Requirement

Exhibit A

Exhibit B

Total

(2 pages)

(2 pages)

(2 pages)

(7 pages-including fax cover sheet)

TO/ISB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FAX RECEIVED

JUL 15 2003

GROUP 1600